review article | Q7318358 |
scholarly article | Q13442814 |
P50 | author | Christoph J Binder | Q54148886 |
Joseph L Witztum | Q62567829 | ||
Sotirios Tsimikas | Q80167861 | ||
P2093 | author name string | Andrew H Lichtman | |
P2860 | cites work | Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70- | Q24594899 |
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4 | Q24634871 | ||
IL-17 and Th17 Cells | Q27860566 | ||
T cell costimulatory and coinhibitory pathways in vascular inflammatory diseases | Q28396774 | ||
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals | Q29615704 | ||
Macrophages in the pathogenesis of atherosclerosis | Q29617765 | ||
CTLA-4 control over Foxp3+ regulatory T cell function | Q29619413 | ||
Regulatory T cells: mechanisms of differentiation and function | Q29620731 | ||
B-cell aortic homing and atheroprotection depend on Id3. | Q30422974 | ||
Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis | Q30425368 | ||
Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice | Q31807203 | ||
Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions | Q33294845 | ||
Innate and adaptive immunity in atherosclerosis | Q33659705 | ||
CD8+ T cell activation predominate early immune responses to hypercholesterolemia in Apoe⁻(/)⁻ mice | Q33761718 | ||
T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses | Q33819043 | ||
Low density lipoprotein undergoes oxidative modification in vivo | Q33838672 | ||
Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis | Q33839918 | ||
CD4(+)CD25(high)CD127(low) regulatory T cells in patients with stable angina and their dynamics after intracoronary sirolimus-eluting stent implantation. | Q33885236 | ||
FcgammaRIIB inhibits the development of atherosclerosis in low-density lipoprotein receptor-deficient mice. | Q43185229 | ||
Resident intimal dendritic cells accumulate lipid and contribute to the initiation of atherosclerosis. | Q43247649 | ||
Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice | Q43455128 | ||
Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice | Q43633700 | ||
Oxidized low-density lipoprotein and atherosclerosis | Q43816762 | ||
Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/- mice | Q43909351 | ||
Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice | Q44149442 | ||
B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice | Q44212443 | ||
Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse | Q44342113 | ||
B7-1/B7-2 costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice | Q44851046 | ||
Interleukin-17A gene variants and risk of coronary artery disease: A large angiography-based study | Q45284956 | ||
Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility | Q45306054 | ||
Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial | Q45369180 | ||
Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. | Q46095021 | ||
Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. | Q46326610 | ||
B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions | Q46365271 | ||
The "atheroprotective" mediators apolipoprotein A-I and Foxp3 are over-abundant in unstable carotid plaques | Q46482317 | ||
The Th17/Treg imbalance in patients with acute coronary syndrome | Q46737661 | ||
Suppression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with beta 2-glycoprotein I. | Q47442034 | ||
Natural killer T cells in lipoprotein metabolism and atherosclerosis. | Q50190286 | ||
The problem of accelerated atherosclerosis in systemic lupus erythematosus: insights into a complex co-morbidity. | Q50417164 | ||
Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. | Q52595013 | ||
Inhibition of IL-17A in atherosclerosis. | Q53080293 | ||
BAFF receptor deficiency reduces the development of atherosclerosis in mice--brief report. | Q53179275 | ||
Interleukin-17 deficiency reduced vascular inflammation and development of atherosclerosis in Western diet-induced apoE-deficient mice. | Q53180650 | ||
High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome. | Q53189579 | ||
CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice. | Q53340266 | ||
Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. | Q53524929 | ||
Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. | Q53591262 | ||
Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. | Q53591922 | ||
Expression of circulatory dendritic cells and regulatory T-cells in patients with different subsets of coronary artery disease | Q39597084 | ||
Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression | Q39601696 | ||
Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice | Q39802780 | ||
Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. | Q40051110 | ||
Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma | Q42162162 | ||
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. | Q42613896 | ||
Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice | Q42757050 | ||
A Critical Function of Th17 Proinflammatory Cells in the Development of Atherosclerotic Plaque in Mice | Q42856694 | ||
CD11c(+) dendritic cells maintain antigen processing, presentation capabilities, and CD4(+) T-cell priming efficacy under hypercholesterolemic conditions associated with atherosclerosis | Q43145952 | ||
Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. | Q53591929 | ||
Activation of Th17/Th1 and Th1, but not Th17, is associated with the acute cardiac event in patients with acute coronary syndrome. | Q54375886 | ||
Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. | Q54412663 | ||
Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. | Q54449577 | ||
Fcgamma receptor deficiency confers protection against atherosclerosis in apolipoprotein E knockout mice. | Q54463267 | ||
Interleukin 17: An unlikely marker of acute coronary syndrome? | Q57515022 | ||
Auto-Antigenic Protein-DNA Complexes Stimulate Plasmacytoid Dendritic Cells to Promote Atherosclerosis | Q57574579 | ||
Regulatory T-Cell Response to Apolipoprotein B100–Derived Peptides Reduces the Development and Progression of Atherosclerosis in Mice | Q58148629 | ||
Natural regulatory T cells control the development of atherosclerosis in mice | Q58149268 | ||
Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis | Q58466080 | ||
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis | Q58992083 | ||
Interleukin-17A Deficiency Accelerates Unstable Atherosclerotic Plaque Formation in Apolipoprotein E-Deficient Mice | Q62735590 | ||
Atherosclerotic lesions in humans. In situ immunophenotypic analysis suggesting an immune mediated response | Q69742103 | ||
Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque | Q69990504 | ||
Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice | Q73288555 | ||
Costimulatory molecules in human atherosclerotic plaques: an indication of antigen specific T lymphocyte activation | Q73701453 | ||
Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease | Q79374759 | ||
CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice | Q80733397 | ||
The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells | Q81161461 | ||
A functional role for inducible costimulator (ICOS) in atherosclerosis | Q81822869 | ||
Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis | Q82102394 | ||
Increased Th17 cells in coronary artery disease are associated with neutrophilic inflammation | Q83176229 | ||
Effect of oral atorvastatin on CD4+CD25+ regulatory T cells, FoxP3 expression, and prognosis in patients with ST-segment elevated myocardial infarction before primary percutaneous coronary intervention | Q83378943 | ||
Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice | Q83491273 | ||
Targeting T cell costimulation to prevent atherothrombosis | Q83683620 | ||
To be 17 again--anti-interleukin-17 treatment for psoriasis | Q83759147 | ||
Counterregulation rules in atherothrombosis | Q83874223 | ||
CD4+LAP + and CD4 +CD25 +Foxp3 + regulatory T cells induced by nasal oxidized low-density lipoprotein suppress effector T cells response and attenuate atherosclerosis in ApoE-/- mice | Q84061197 | ||
Cellular immunity, low-density lipoprotein and atherosclerosis: break of tolerance in the artery wall | Q85054596 | ||
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) | Q85063666 | ||
Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells | Q33967700 | ||
B cell depletion reduces the development of atherosclerosis in mice | Q34044387 | ||
Deficiency of antigen-presenting cell invariant chain reduces atherosclerosis in mice | Q34082315 | ||
Depletion of B2 but not B1a B cells in BAFF receptor-deficient ApoE mice attenuates atherosclerosis by potently ameliorating arterial inflammation | Q34125054 | ||
The immune system in atherosclerosis | Q34164644 | ||
Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials | Q34189897 | ||
TAP1-deficiency does not alter atherosclerosis development in Apoe-/- mice | Q34221791 | ||
T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein | Q34390132 | ||
Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. | Q34582934 | ||
Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis | Q34601335 | ||
The inhibitory FcγRIIb modulates the inflammatory response and influences atherosclerosis in male apoE(-/-) mice | Q34644753 | ||
Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study | Q34654209 | ||
Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis | Q34661745 | ||
CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells | Q34709777 | ||
Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis | Q34737721 | ||
Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice | Q34789613 | ||
Innate and acquired immunity in atherogenesis | Q34986341 | ||
Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation | Q35013382 | ||
Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice | Q35050827 | ||
Deleting TCR alpha beta+ or CD4+ T lymphocytes leads to opposite effects on site-specific atherosclerosis in female apolipoprotein E-deficient mice | Q35103567 | ||
Dynamic changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia | Q35133174 | ||
Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature | Q35168945 | ||
IgE stimulates human and mouse arterial cell apoptosis and cytokine expression and promotes atherogenesis in Apoe-/- mice | Q35187080 | ||
Antigen presentation to naive CD4 T cells in the lymph node. | Q35187925 | ||
Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study | Q35212898 | ||
Attenuated atherosclerotic lesions in apoE-Fcγ-chain-deficient hyperlipidemic mouse model is associated with inhibition of Th17 cells and promotion of regulatory T cells | Q35566640 | ||
CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice | Q35572404 | ||
Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events | Q35592510 | ||
Cancer immunotherapy comes of age | Q35666338 | ||
Autoimmune and inflammatory mechanisms in atherosclerosis | Q35698466 | ||
The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice | Q35792034 | ||
Immunology of atherosclerosis. Demonstration of heat shock protein 60 expression and T lymphocytes bearing alpha/beta or gamma/delta receptor in human atherosclerotic lesions. | Q35833004 | ||
In vivo detection of oxidation-specific epitopes in atherosclerotic lesions using biocompatible manganese molecular magnetic imaging probes | Q35905632 | ||
The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment | Q35915712 | ||
Statins induce the accumulation of regulatory T cells in atherosclerotic plaque | Q36071708 | ||
Lymphocytes are important in early atherosclerosis | Q36072647 | ||
Mechanisms of suppression by suppressor T cells | Q36078047 | ||
T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse | Q36142970 | ||
Interleukin-4 does not influence development of hypercholesterolemia or angiotensin II-induced atherosclerotic lesions in mice | Q36202916 | ||
How dendritic cells shape atherosclerosis | Q36235238 | ||
Human "orchestrator" CD11b(+) B1 cells spontaneously secrete interleukin-10 and regulate T-cell activity | Q36283440 | ||
Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype | Q36379539 | ||
Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis | Q36399030 | ||
Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory | Q36399652 | ||
IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis | Q36849075 | ||
Caveolin-1 deficiency decreases atherosclerosis by hampering leukocyte influx into the arterial wall and generating a regulatory T-cell response | Q36903682 | ||
Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease. | Q37037196 | ||
The role of adaptive T cell immunity in atherosclerosis | Q37339539 | ||
IFN-gamma potentiates atherosclerosis in ApoE knock-out mice | Q37368296 | ||
The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/- mice | Q37372718 | ||
Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis | Q37377439 | ||
Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice | Q37385727 | ||
Inhibition of arterial lesion progression in CD16-deficient mice: evidence for altered immunity and the role of IL-10. | Q37467868 | ||
Vaccination against atherosclerosis? Induction of atheroprotective immunity | Q37495603 | ||
Interleukin-17: friend or foe in atherosclerosis? | Q37777607 | ||
Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives | Q37812524 | ||
Complement in atherosclerosis: friend or foe? | Q37820714 | ||
Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity | Q37830940 | ||
The infectious burden in atherothrombosis | Q37848724 | ||
IL-17A Is Proatherogenic in High-Fat Diet-Induced and Chlamydia pneumoniae Infection-Accelerated Atherosclerosis in Mice | Q37852203 | ||
Mechanisms for the anti-inflammatory effects of statins | Q37853818 | ||
Recent advances on the role of cytokines in atherosclerosis | Q37867358 | ||
Deciphering the role of Th17 cells in human disease | Q37940695 | ||
Atherosclerosis: current pathogenesis and therapeutic options | Q37953777 | ||
A killer on the road: circulating CD4(+)CD28null T cells as cardiovascular risk factor in ESRD patients. | Q37963812 | ||
Immune regulatory function of B cells. | Q37973774 | ||
Phenotypic and functional heterogeneity of macrophages and dendritic cell subsets in the healthy and atherosclerosis-prone aorta | Q37998021 | ||
Inhibition of interleukin-5 for the treatment of eosinophilic diseases. | Q38006131 | ||
Apolipoprotein B100 autoimmunity and atherosclerosis - disease mechanisms and therapeutic potential | Q38027749 | ||
Late developmental plasticity in the T helper 17 lineage | Q39265291 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 27-36 | |
P577 | publication date | 2013-01-02 | |
P1433 | published in | Journal of Clinical Investigation | Q3186904 |
P1476 | title | Adaptive immunity in atherogenesis: new insights and therapeutic approaches | |
P478 | volume | 123 |